MedTrace Logo

TGF-(Beta) and Susceptibility to RSV

NCT01224691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2026-05-07

No results posted yet for this study

Summary

Background:

* Human respiratory syncytial virus (RSV) is a virus that causes respiratory tract infections, and is frequently responsible for hospital visits in infants and children. It can also trigger severe breathing problems for individuals who have asthma, but these infections are generally better tolerated in non-asthmatics. Some research suggests that lack of an efficient immune system response in people with asthma may make it difficult for the body to fight the effects of RSV.
* Transforming Growth Factor-beta (TGF-\[beta\]) is a chemical in the body that is more prevalent in the lungs of people with asthma and related respiratory disorders. More information is needed about the effects of TGF-\[beta\] and whether it makes individuals with asthma more prone to developing RSV. Researchers hope to use this information to determine possible treatments and therapies for individuals with asthma who contract RSV.

Objectives:

\- To determine the possible role of TGF-\[beta\] in increased asthmatic susceptibility to RSV infection.

Eligibility:

\- Individuals between 18 and 60 years of age who are either healthy nonsmokers or mild asthmatics.

Design:

* This study involves a screening visit and a study visit.
* Participants will be screened with a medical history and physical examination, as well as blood samples and a pulmonary function test.
* At the study visit, participants will receive mild anesthetic and have a bronchoscopy, in which researchers insert a bronchoscope through the participant s nose or mouth and into the lungs to examine the lungs and collect lung cells.
* Participants will be contacted by a research team member 24 36 hours after the bronchoscopy to ask about any side effects from the procedure.

Conditions

Sponsors & Collaborators

  • National Institute of Environmental Health Sciences (NIEHS)

    lead NIH

Principal Investigators

  • Stavros Garantziotis, M.D. · National Institute of Environmental Health Sciences (NIEHS)

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224691 on ClinicalTrials.gov